A Randomized, Open-Label Pilot Trial to Evaluate the Safety and Efficacy of Carmustine Wafer in Combination with Retifanlimab and Standard Radiation With or Without Temozolomide in Newly-Diagnosed Adult Subjects with Glioblastoma

Multiple Cancer Types

A Phase 3, Multicenter, Randomized, Open-Label Study of ABBV-383 Compared with Standard Available Therapies in Subjects with Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study)

A Phase I/Ib Study Evaluating Single-Agent Inavolisib and Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers

Multiple Cancer Types

AssesSing a Biomarker PlatfOrm for STratifying IndeterminaTe Pulmonary Nodules; The SPOT IT Platform Trial

Lung

Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtagene Ciloleucel

Lymphoma

A Randomized Phase II Study of Sotorasib versus Continued Consolidation Durvalumab in Patients with KRAS G12C Mutant Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC) with Persistent ctDNA Defined Minimal Residual Disease

Lung

A Phase 3, Randomized Study of Adjuvant Cretostimogene Grenadenorepvec versus Observation for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC) Following Transurethral Resection of Bladder Tumor (TURBT)

Bladder

A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination with Nivolumab versus Ipilimumab in Combination with Nivolumab in Immune Checkpoint Inhibitor-Nave Adult Patients with Metastatic Uveal Melanoma

An Open-label, Phase 1 Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of SMP-3124LP in Adults with Advanced Solid Tumors

Multiple Cancer Types

A Phase II Trial Evaluating Chemotherapy followed by Response-Based Reduced Radiation Therapy for Patients with Central Nervous System Germinomas